X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أبريل 2022 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

17 مارس 2022 06:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

08 مارس 2022 08:00:03 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at March Investor Conferences

03 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 فبراير 2022 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

19 يناير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 يناير 2022 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

13 ديسمبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

11 ديسمبر 2021 09:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

02 ديسمبر 2021 06:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ديسمبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference

10 نوفمبر 2021 08:00:02 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

04 نوفمبر 2021 09:01:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

25 أكتوبر 2021 08:00:01 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

19 أكتوبر 2021 08:00:02 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

04 أكتوبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أكتوبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

15 سبتمبر 2021 16:05:00 بحسب Nasdaq GlobeNewswire